Vycellix CEO to Present Next-Generation Universal Cell Platform to Optimize Allogeneic Cell Therapies at ‘Innate Killer Summit’

On August 10, 2020 Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, reported that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Innate Killer Summit (Press release, Vycellix, AUG 10, 2020, View Source;utm_medium=rss&utm_campaign=vycellix-ceo-to-present-next-generation-universal-cell-platform-to-optimize-allogeneic-cell-therapies-at-innate-killer-summit [SID1234563248]). The Conference, which will be held as a virtual event on August 25-26, is the largest industry-focused meeting concentrating on all aspects of innate immunity and NK cell therapy breakthroughs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vycellix Presentation Details:

Event: Innate Killer Summit (virtual conference)
Presenter: Evren Alici, M.D., Ph.D., Chairman & CEO, Vycellix, Inc.
Day/Time: Wednesday, August 26 at 9:30am ET
Title: Strategies to Generate Potent NK Cells as Universal Source
Link: View Source

Dr. Alici’s presentation will include discussion reporting on Vycellix’s VY-UC platform, designed to generate immune-privileged universal cells without altering the components that control self-recognition (HLA). Cells modified by VY-UC avoid immune recognition of grafted cells without impacting HLA while conserving viability, functionality, and persistence.

According to Dr. Alici, "We developed VY-UC to abrogate cellular immune response while obviating the need for immune-suppressive drugs in contexts of allogeneic cell therapies, hence redefining ‘off-the-shelf’ treatment strategies for a broad range of uses and indications, including for the development of next-generation NK cells." Dr. Alici is group leader in Hematology at Karolinska Institutet (KI), Department of Medicine, Stockholm, Sweden. He also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI.